Olaparib
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD + at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single-strand breaks (SSBs) mediated via the base excision repair (BER) pathway. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of deleterious double-strand breaks (DSBs). In cells with an intact homologous recombination (HR) pathway, these DSBs can be repaired effectively. However, in tumors with homologous recombination repair deficiencies, olaparib causes synthetic lethality through the combination of two molecular events that are otherwise nonlethal when occurring in isolation. Olaparib is already approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefits among such patients. It has also shown promising activity in patients with metastatic breast or prostate cancer and a germline BRCA mutation. Besides its usage as a single agent, olaparib can also act either as a chemo- and/or radiosensitizer, due to its ability to potentiate the cytotoxic effects of these therapeutic agents. However, a clear patient benefit for the latter application has not been demonstrated yet.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Its mechanism of action involves the trapping of PARP on damaged DNA, leading to cell death, especially in cells deficient in homologous recombination repair (HRR) [29].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [29]
In the citing paper
“When combined with drugs targeting other pathways, such as angiogenesis inhibitors, immune checkpoint blockers, or chemotherapy agents, can lead to synergistic effects [29].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [29]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Cited by
Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5
Hrubša, M., Siatka, T., Nejmanová, I., Vopršalová, M., Kujovská Krčmová, L., Matoušová, K., Javorská, L., Macáková, K., Mercolini, L., Remião, F., et al. (2022) · Nutrients · doi:10.3390/nu14030484 · Cited by 263
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
Lou, X., Chen, Z., He, Z., Sun, M., & Sun, J. (2021) · Nano-Micro Letters · doi:10.1007/s40820-020-00560-9 · Cited by 138
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., & Xu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114109 · Cited by 136
Sabit, H., Adel, A., Abdelfattah, M. M., Ramadan, R. M., Nazih, M., Abdel-Ghany, S. E., El-Hashash, A. H. K., & Arneth, B. M. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217865 · Cited by 125
PARP inhibitors in gastric cancer: beacon of hope
Wang, Y., Zheng, K., Huang, Y., Xiong, H., Su, J., Chen, R., & Zou, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02005-6 · Cited by 66
Metadata
- Authors
- Bochum, S., Berger, S., & Martens, U. M.
- Affiliations
- SLK-Kliniken Heilbronn (DE)
- Corresponding author
- Bochum, Sylvia
- Venue
- Recent Results in Cancer Research
- Publisher
- Springer International Publishing
- Published
- 2018
- Volume
- 211
- Pages
- 217-233
- ISSN
- 0080-0015 (ISSN-L)
- 2197-6767
- OpenAlex
- W4255412302
- Cited by
- 104
- References
- 59
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 17 · 2023: 22 · 2022: 16 · 2021: 12 · 2020: 6 · 2019: 3
- FWCI
- 13.93
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, PARP1, PARP2, base excision repair, single-strand breaks, DNA double-strand break repair, homologous recombination deficiency, synthetic lethality, BRCA mutations, recurrent ovarian cancer, metastatic breast cancer, metastatic prostate cancer, radiosensitization, chemosensitization
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Phthalazines, Piperazines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olaparib. https://app.cochat.ai/papers/10.1007/978-3-319-91442-8_15
- The paper
- Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Recent Results in Cancer Research. https://doi.org/10.1007/978-3-319-91442-8_15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.